Form 8-K
8-K — CONMED Corp
Accession: 0002077096-26-000203
Filed: 2026-06-17
Period: 2026-06-17
CIK: 0000816956
SIC: 3845 (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS)
Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item: Regulation FD Disclosure
Item: Financial Statements and Exhibits
Documents
8-K — ea0295016-8k_conmed.htm (Primary)
EX-10.1 — LETTER AGREEMENT, DATED MAY 28, 2026, BY AND BETWEEN THE COMPANY AND JOHN E. GALLAGHER (ea029501601ex10-1.htm)
EX-99.1 — PRESS RELEASE ISSUED BY CONMED CORPORATION DATED JUNE 17, 2026 (ea029501601ex99-1.htm)
GRAPHIC (ea029501601_ex10-1img1.jpg)
GRAPHIC (ea029501601_ex10-1img2.jpg)
GRAPHIC (ea029501601_ex99-1img1.jpg)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K — CURRENT REPORT
8-K (Primary)
Filename: ea0295016-8k_conmed.htm · Sequence: 1
false
0000816956
0000816956
2026-06-17
2026-06-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
June 17, 2026
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
001-39218
16-0977505
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
11311 Concept Blvd
Largo, FL
33773
(Address of principal executive offices)
(Zip code)
(727) 392-6464
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (See General Instruction A.2
below):
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Rule 12(b) of
the Act
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 par value
CNMD
NYSE
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 17, 2026, CONMED Corporation (the “Company”) announced
that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning
July 15, 2026 (the “Effective Date”). Mr. Gallagher will also be the Company’s principal financial officer and principal
accounting officer.
Mr. Gallagher, age 53, will join the Company from Certara, Inc., a
publicly traded pharmaceutical technology and services company, where he has served as Chief Financial Officer since April 2023. Prior
to joining Certara, Mr. Gallagher served as Chief Financial Officer of Cue Health Inc., a publicly traded healthcare technology company,
from 2021 to 2023. Prior to Cue Health, Mr. Gallagher served as Senior Vice President, CFO of the Medical Segment and Treasurer of Becton,
Dickinson & Co., a multinational medical technology company. Mr. Gallagher joined Becton Dickinson in 2012 as Corporate Treasurer
and also served as Chief Accounting Officer during his time there. Prior to joining Becton Dickinson, Mr. Gallagher served in a variety
of finance leadership positions at NBC Universal, General Electric Company and Ford Motor Company. Mr. Gallagher received his MBA from
the Joseph M. Katz Graduate School of Business at the University of Pittsburgh and a B.S. in Finance from Clemson University.
There are no arrangements or understandings between Mr. Gallagher and
any other person pursuant to which he was appointed as Chief Financial Officer. There are no family relationships between Mr. Gallagher
and any director or officer of the Company, nor does Mr. Gallagher have any direct or indirect material interest in any transaction required
to be disclosed pursuant to Item 404(a) of Regulation S-K.
In connection with his appointment, Mr. Gallagher and the Company entered
into a letter agreement that sets forth the terms and conditions of his employment (the “Letter Agreement”). Mr. Gallagher’s
annual base salary will be $650,000, and he will be eligible for an annual cash bonus targeted at 85% of his base salary, subject to achievement
of certain performance metrics. The Letter Agreement also provides for grants to Mr. Gallagher on the Effective Date pursuant to the Company’s
2025 Long-Term Incentive Plan (the “2025 Long-Term Incentive Plan”) of (a) (i) options to purchase common shares of the Company
with a grant value of $575,000, (ii) restricted stock units with grant value of $1,150,000 and (iii) performance stock units with a grant
value of $575,000 and (b) restricted stock units with a grant value of $1,500,000, subject to the approval of the Company’s Compensation
Committee, as a make-whole in connection with certain equity awards forfeited from a prior employer. In addition, Mr. Gallagher will receive
a one-time cash bonus payment of $34,750 if he remains employed by the Company on December 31, 2026.
Mr. Gallagher will also participate in the CONMED Corporation Executive
Severance Plan (the “Severance Plan”). Under the Severance Plan, if Mr. Gallagher is terminated by the Company other than
for Cause (as defined in the Severance Plan) prior to, or more than two years following, a Change in Control (as defined in the Severance
Plan) and signs a customary release of claims, Mr. Gallagher will receive: (i) a lump sum cash payment equal to 1.5 times his base salary;
(ii) a lump sum cash payment equal to 1.5 times the average of his Annual Incentive Awards (as defined in the Severance Plan) earned for
the two completed fiscal years immediately preceding the year of termination; and (iii) continued participation in the Company’s
group health plans for the maximum period permitted under COBRA. If, during the two-year period following a Change in Control, Mr. Gallagher
is terminated by the Company other than for Cause or Mr. Gallagher resigns for Good Reason (as defined in the Severance Plan) and signs
a customary release of claims, Mr. Gallagher will receive: (i) a lump sum cash payment equal to 2.5 times his base salary; (ii) a lump
sum cash payment equal to 2.5 times the average of his Annual Incentive Awards earned for the three completed fiscal years immediately
preceding the year of termination; and (iii) continued participation in the Company’s group health plans for the maximum period permitted
under COBRA. In the event that any payments or benefits payable to Mr. Gallagher would constitute “parachute payments” within
the meaning of Section 280G of the Internal Revenue Code (the “Code”) and would be subject to the excise tax imposed by Section
4999 of the Code, such payments and benefits will be either delivered in full or reduced to the lesser extent that would result in no
portion being subject to such excise tax, whichever results in the greater after-tax benefit to Mr. Gallagher.
The foregoing description of the Letter Agreement is not
complete and is qualified in its entirety by reference to the full text of the Letter Agreement, a copy of which is filed as
Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Upon the Effective Date, Patrick Beyer will cease to be the Company’s
Interim Principal Financial Officer, but he will continue to serve as the Company’s President and Chief Executive Officer. In addition,
Kimberly Lockwood will cease to be the Company’s Interim Principal Accounting Officer, but she will remain Interim Corporate Controller
and Senior Director, Financial Reporting and Controls.
1
Item 7.01 Regulation
FD Disclosure.
On June 17, 2026, the Company issued a press release announcing the
matters described above, a copy of which is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information furnished herewith pursuant to Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration
statement or other document under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
Exhibit Number
Description
10.1
Letter Agreement, dated May 28, 2026, by and between the Company and John E. Gallagher.
99.1
Press Release issued by CONMED Corporation dated June 17, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
Signature
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 17, 2026
CONMED CORPORATION
(Registrant)
By:
/s/ Patrick Beyer
Name:
Patrick Beyer
Title:
President and Chief Executive Officer and Interim Principal Financial Officer
3
EX-10.1 — LETTER AGREEMENT, DATED MAY 28, 2026, BY AND BETWEEN THE COMPANY AND JOHN E. GALLAGHER
EX-10.1
Filename: ea029501601ex10-1.htm · Sequence: 2
Exhibit 10.1
John D. Ferrell
Executive Vice President, HR
CONMED Corporation
11311 Concept Blvd.
Largo, FL 33773
May 28, 2026
John Gallagher
331 Indian Trail Drive
Franklin Lakes, NJ 07417
RE: Offer of Employment between John Gallagher and CONMED Corporation
(“CONMED”)1
Dear John,
I am pleased to provide this written offer to have you join CONMED
as Chief Financial Officer. As we have discussed, this offer is contingent on formal approval by the Compensation Committee and Board
of Directors, and your written acceptance of the terms and conditions included in this offer letter (the “Agreement”):
1. Position.
Your position will be Executive Vice President, Chief Financial Officer, based Remotely and reporting to Pat Beyer, President and Chief
Executive Officer.
2. Effective
Date. We anticipate a start date of July 6, 2026, unless otherwise agreed (“Effective Date”).
3. Base
Salary. Beginning on the Effective Date, your annual base salary will be $650,000.00/year, paid semi-monthly (or otherwise in accordance
with the CONMED’s regular payroll practices).
4. Annual
Bonus. You will be eligible to participate in our Executive Bonus Plan (as it may be amended from time to time). Your target annual
bonus is 85% of your base salary. Actual bonus amounts earned, if any, are determined in CONMED’s sole discretion. This bonus is
subject to the terms and conditions of our Executive Bonus Plan; a copy of CONMED’s current Executive Bonus Plan is being provided
to you with this Agreement. Your 2026 bonus will be prorated based on (A) the target bonus multiplied by (B) a fraction equal to the number
of calendar days serving as the Executive Vice President, Chief Financial Officer divided by 365 days.
5. Bonus. Provided that you are employed
in good status on December 31, 2026, you will be paid a one-time bonus of $34,750, which shall be subject to applicable withholdings
and deductions.
1 Any reference to CONMED shall mean CONMED Corporation and
its affiliated entities.
6. Long-Term
Incentive Compensation.
a) As
of the Effective Date, you will be awarded an equity grant with a grant value of $2,300,000 comprised of 50% Restricted Stock Units (“RSUs”),
25% Performance Stock Units (at target) (“PSUs”) and 25% Stock Options. All equity awards will be subject to the terms of
2025 Long-Term Incentive Plan (as it may be amended or superseded from time to time, the “Long-Term Incentive Plan”) and the
applicable award agreements evidencing such awards, which shall contain the terms and conditions of the awards, including the vesting
provisions, and which shall control in the event of a conflict with this Section.
b) As
of the Effective Date, in order to make you whole for certain equity awards that you are forfeiting from a prior employer, subject to
the approval of the Compensation Committee, you will be awarded a one-time grant of RSUs with a grant value of $1,500,000 (the “Make-Whole
RSUs”). The Make-Whole RSUs will vest in three substantially equal installments on each of the first three anniversaries of the
Effective Date and will be subject to the terms of the Long-Term Incentive Plan and the award agreement evidencing such award, which shall
control in the event of a conflict with this Section.
c) In
addition, during your employment with CONMED, you will be eligible to participate in CONMED’s Long-Term Incentive plan in a manner
consistent with other senior leaders of the Company. The Company generally makes annual grants in March of each calendar year (which grant
timing is subject to change). Subject to approval of the Compensation Committee and subject to your continued employment, on or around
March 1, 2027, you will be granted long-term incentive awards for the 2027 fiscal year comprised of PSUs, Options and RSUs as determined
by the Compensation Committee.
d) As
an executive leader at CONMED, you will be subject to the Equity Ownership Guidelines established by the Board and other policies applicable
to holding CONMED equity, as in effect from time to time.
7. Classification
and Location. This is a full-time, exempt position. You will be expected to travel as necessary or requested to fulfill your responsibilities.
Your employment is at-will and may be terminated by either party at any time, with or without cause.
8. Paid
Time Off (“PTO”) Policy. At CONMED we believe in the philosophy of employees working hard and living fully. CONMED’s
exempt PTO policy gives employees the opportunity to work or take time off as they see fit, so long as the employee continues to
achieve performance expectations set with their manager.
9. Employee
Benefits; Policies. You will be entitled to participate in all employee benefits that CONMED has adopted or may adopt, maintain
or contribute to for the benefit of its executives at a level commensurate with your position subject to satisfying any applicable
eligibility requirements, as such benefit plans may be in effect or amended from time to time. You will be eligible to participate in
CONMED’s 401(k) plan under the same terms as other participating employees. This plan currently provides a company match up to 7%
of your eligible compensation, not to exceed $10,000 per year. You agree that, while employed by CONMED, you will operate with the utmost
integrity and comply with all Company policies, practices and procedures and codes of ethics or business conduct, as in effect from time
to time.
Page 2 of 7
10. Severance.
You will be eligible to participate in the CONMED Corporation Executive Severance Plan at the “Senior Executive Level” in
accordance with the terms of such plan, as it may be amended and in effect from time to time.
11. Covenants.
a) Protection
of Confidential Information. During the term of employment and thereafter, you will (i) hold all Confidential Information in
strict confidence and take all reasonable precautions to protect it from disclosure, (ii) not use or disclose such Confidential Information
except as necessary to perform your duties for CONMED or as expressly authorized in writing by CONMED, and (iii) you will not, directly
or indirectly, disclose or otherwise communicate Confidential Information to anyone outside of the CONMED or use Confidential Information
for yourself or otherwise, either during or after the period of your employment (except as required for the proper performance of your
regular duties for the Company). For purposes of this Agreement, “Confidential Information” means all non-public, proprietary,
or confidential information of the CONMED, whether disclosed orally, electronically, or in writing, that you obtain or develop in the
course of employment. Confidential Information includes, without limitation: financial statements (including forecasts, budgets, and liquidity
analyses); earnings data and guidance; capital structure and financing arrangements; merger, acquisition, and divestiture plans; investor
relations strategies; internal controls, audit materials, and compliance matters; tax strategies; pricing, cost, and margin data; supplier
and customer information; intellectual property, trade secrets; business plans; strategic initiatives; Board and committee materials;
and any other information that derives independent economic value from not being generally known. Upon termination of employment or upon
CONMED’s request at any time, you shall promptly return or destroy (at CONMED’s direction) all documents, files, records,
and other materials, whether in physical or electronic form, containing Confidential Information, including all copies, summaries, and
extracts, and certify compliance upon request.
b) Non-Competition.
During your employment with CONMED and for the period one (1) year immediately following termination of your employment with CONMED for
any reason (the “Restricted Period”), you will:
i) not
anywhere in the United States or any other country in which CONMED operates, directly or indirectly (whether as principal, agent, independent
contractor, employee or otherwise), own, manage, organize, operate, join, control or otherwise carry on, participate in the ownership,
management, organization, operation or control of, or be engaged in or concerned with, any business competitive with that of CONMED (a
“Competing Business”), provided that you will not be prohibited from owning less than 5% of any publicly traded corporation,
whether or not such corporation is in competition with CONMED;
Page 3 of 7
ii) inform
any person who, or entity which, seeks to engage your services that you are bound by this Section and the other terms of this Agreement;
and
iii) not
(x) solicit by mail, by telephone, by personal meeting, or by any other means, either directly or indirectly, any known customer or any
individual or entity specifically identified as, and known to be, a prospective customer of CONMED to transact any Competing
Business or to reduce or refrain from doing any business with CONMED, or (y) knowingly interfere with or damage (or attempt to interfere
with or damage) any relationship between CONMED and any such customer or prospective customer.
c) Non-Solicitation.
During the Restricted Period, you will not solicit, aid or induce (directly or indirectly, on your own behalf or on behalf of any individual
or entity other than CONMED) any then current employee, representative or agent of CONMED to leave such employment or retention or to
accept employment with or render services to or with any other person, firm, corporation or other entity unaffiliated with CONMED
or hire or retain any such employee, representative or agent, or take any action to assist or aid any other person, firm, corporation
or other entity in identifying, hiring or soliciting any such employee, representative or agent.
d) Non-Disparagement.
While you are employed by CONMED and at all times thereafter, you agree not to make negative comments or otherwise disparage CONMED or
any of its officers, directors, employees, shareholders, agents or products, in any manner likely to be harmful to them or their
business, business interests, business reputation or personal reputation. Notwithstanding the foregoing, nothing herein shall prevent
you from testifying truthfully in any legal or administrative proceeding where such testimony is compelled or requested, or from otherwise
complying with applicable legal requirements, or limit or restrict your right to make disclosures of information as otherwise provided
in subsection (e) below.
e) Protected
Activity. Notwithstanding anything herein to the contrary, this Agreement shall not limit your rights under applicable law to initiate
communications directly with, provide information to, respond to any inquiries from, or report possible violations of law or regulation
to any governmental entity or self-regulatory authority, or to file a charge with or participate in an investigation conducted by
any governmental entity or self-regulatory authority, and you do not need CONMED’s permission to do so. In addition, it is understood
that this Agreement shall not require you to notify CONMED of a request for information from any governmental entity or self-regulatory
authority that is not directed to CONMED or of your decision to file a charge or complaint with or participate in an investigation
conducted by any governmental entity or self-regulatory authority. Notwithstanding the foregoing, you recognize that, in connection with
the provision of information to any governmental entity or self-regulatory authority, you must inform such governmental entity or self-regulatory
authority that the information you are providing is confidential. You further understand that you cannot be held criminally or civilly
liable under any federal or state trade secret law for disclosing a trade secret (i) in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney, solely for the purpose of reporting or investigating a suspected violation
of law, or (ii) in a complaint or other document filed under seal in a lawsuit or other proceeding; provided that, notwithstanding this
immunity from liability, you understand that you may be held liable if you unlawfully access trade secrets by unauthorized means. Nothing
in this Agreement shall be deemed a waiver of any applicable privilege, including the attorney-client privilege and attorney work product
doctrine. The Company reserves all rights to assert such privileges. For the avoidance of doubt, this provision does not limit or restrict
your rights under applicable law to communicate with any governmental entity or self-regulatory authority, including providing documents
or information.
Page 4 of 7
f) Remedies.
If you commit a breach of, or threaten to breach any of the provisions of this Section, in addition to CONMED’s rights to terminate
any and all of its obligations hereunder, CONMED will have the right to an injunction or order of specific enforcement, without necessity
of posting a bond or providing independent evidence of irreparable injury, by any court having jurisdiction, it being acknowledged and
agreed that any such breach or threatened breach will cause irreparable injury to CONMED, and that money damages will not provide an adequate
remedy to CONMED. You and CONMED recognize that the laws and public policies of various jurisdictions may differ as to the validity and
enforceability of agreements similar to those contained in this Section. It is the intention of you and CONMED that the provisions of
this Section will be enforced to the fullest extent permissible under the laws and public policies of each jurisdiction in which such
enforcement is sought. You and CONMED further agree that, in the event that any provision of this Section is determined by any court of
competent jurisdiction to be unenforceable by reason of its being extended over too great a time, too large a geographic area or too great
a range of activities, that provision shall be deemed to be modified to permit its enforcement to the maximum extent permitted by law.
g) Tolling.
In the event of any violation of the provisions of this Section, you acknowledge and agree that the post-termination restrictions contained
in this Section will be extended by a period of time equal to the period of such violation, it being the intention that the running of
the applicable post-termination restriction period will be tolled during any period of such violation.
h) Survivability.
The obligations contained in this Section will survive the termination of your employment with CONMED and will be fully enforceable thereafter.
i) Acknowledgement.
You specifically acknowledge and agree that the restrictions in this Section are necessary and reasonable for the protection of CONMED’s
trade secrets, Confidential Information and customer goodwill.
Page 5 of 7
12. Applicable
Law; Choice of Forum
a) Excepting
any claim for benefits under any employee benefit plan in which you are a participant (which claims shall be determined in accordance
with the terms of such plan), to the fullest extent permitted by law, all claims that you may have against CONMED or any other controversy
arising under, or otherwise relating to, the terms of your employment with and services rendered by you to CONMED shall be governed by,
and construed exclusively in accordance with, the laws of the State of New Jersey.
b) The
federal or state courts in New Jersey shall have exclusive jurisdiction (and shall be the exclusive forum) in the event of any claim or
dispute you may raise or assert arising under or relating to the terms of your employment with and services rendered by you to CONMED.
c) CONMED
shall be free to bring any suit or claim relating to the enforcement of the terms of this Agreement in any court of competent jurisdiction.
d) THE PARTIES HEREBY WAIVE ANY RIGHTS THEY
MAY HAVE TO TRIAL BY JURY, INCLUDING WITHOUT LIMITATION ANY RIGHT TO TRIAL BY JURY AS TO THE MAKING, EXISTENCE, VALIDITY, OR
ENFORCEABILITY OF THIS AGREEMENT.
13. Forfeiture;
Recoupment of Incentive Compensation. All annual, long-term and other incentive compensation hereunder or pursuant to any plan, program
or other agreement in which you are a participant or a party shall be subject to cancellation, forfeiture and recoupment by CONMED, and
shall be repaid by you to CONMED, to the extent required by law, regulation or stock exchange listing requirement, or as may be required
pursuant to any Company corporate governance guidelines or policies and to any similar or successor provisions as may be in effect from
time to time. You acknowledge that you are subject to the CONMED Corporation Policy for the Recovery of Erroneously Awarded Incentive-Based
Compensation and will execute an acknowledgement provided to you by CONMED to that effect.
14. Miscellaneous.
a) Entire
Agreement; Amendments; No Waiver. This Agreement supersedes all previous agreements whether written or oral between you and CONMED
and constitutes the entire agreement and understanding between CONMED and you concerning the subject matter hereof. If, and to the extent
that, any other written or oral agreement between you and CONMED is inconsistent with or contradictory to the terms of this Agreement,
the terms of this Agreement shall apply. No modification, amendment, termination, or waiver of this Agreement shall be binding unless
in writing and signed by you and a duly authorized officer of CONMED. Failure of any party to insist upon strict compliance with
any of the terms, covenants, or conditions hereof shall not be deemed a waiver of such terms, covenants, and conditions.
Page 6 of 7
b) Employment
Eligibility. This Agreement is contingent upon CONMED’s completion of satisfactory background and reference checks, as well
as its verification of your eligibility for employment within three business days of the Effective Date pursuant to the Immigration Reform
and Control Act.
c) Conflicting
Agreements. You hereby represent and warrant that your signing of this Agreement and the performance of your obligations under it
will not breach or be in conflict with any other agreement to which you are a party or are bound, and that you are not now subject to
any covenants against competition or similar covenants or any court order that could affect the performance of your obligations under
this Agreement. You agree that you will not disclose to or use on behalf of CONMED any confidential or proprietary information of a third
party without that party’s consent.
d) Successors
and Assigns. This Agreement is binding upon and shall inure to the benefit of you and your heirs, executors, assigns and administrators
of your estate and CONMED and its successors and permitted assigns. You may not assign or transfer to others the obligation to perform
your duties hereunder. The Company may not assign this Agreement other than to an affiliate or to a successor to all or substantially
all of its business.
e) Withholding.
All payments made by CONMED under this Agreement shall be reduced by any tax or other amounts required to be withheld by CONMED to the
extent required by applicable law.
f) Construction.
It is the parties’ intention that this Agreement not be construed more strictly with regard to you or CONMED.
g) Counterparts.
This Agreement may be signed in counterparts each of which will be deemed an original, but all of which will constitute one and the same
instrument. This Agreement may be executed by a signature delivered by facsimile or in e-mail/PDF or other electronic format.
John, congratulations on being offered the position of Chief Financial
Officer. We are very excited to have you join us.
Sincerely,
John D. Ferrell
Executive Vice President, HR
Page 7 of 7
EX-99.1 — PRESS RELEASE ISSUED BY CONMED CORPORATION DATED JUNE 17, 2026
EX-99.1
Filename: ea029501601ex99-1.htm · Sequence: 3
Exhibit 99.1
NEWS RELEASE
CONTACT:
CONMED Corporation
Dalton Henry
Investor Relations Analyst
IR@conmed.com
CONMED Corporation Appoints John E.
Gallagher as Chief Financial Officer
Largo, Fla. – June 17, 2026 –
CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”),
effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2,
2026.
“We are pleased to welcome a talented
and experienced financial executive of John’s caliber to CONMED,” said Patrick J. Beyer, CONMED’s President and
Chief Executive Officer. “John brings deep healthcare and medical technology experience, an extensive history of public
company leadership, and a proven track record of leading global finance organizations and supporting complex strategic initiatives.
His combination of industry expertise, financial leadership, and operational partnership experience make him exceptionally
well-positioned to help CONMED execute its strategic priorities. I am excited to work alongside John as we focus on our strategic
priorities, delivering strong execution, and creating long-term value for our shareholders.”
Mr. Gallagher brings nearly three decades of financial
experience to CONMED, leading corporate finance, treasury, investor relations, financial planning and analysis, accounting, business
performance management, and capital markets activities across public healthcare and industrial companies. Most recently, he served as
CFO of Certara, Inc., a publicly traded pharmaceutical technology and services company, beginning in 2023. Prior to Certara, he served
as CFO of Cue Health Inc., a healthcare technology company, from 2021 to 2023. Mr. Gallagher previously worked for Becton, Dickinson &
Co. (“BD”), where he served in multiple roles over the course of 9 years. Upon joining BD in 2012, Mr. Gallagher was named
Corporate Treasurer, a role he held throughout his tenure at the company. He was also responsible for corporate finance, including leading
FP&A, and was Controller/Chief Accounting Officer during two transformative acquisitions. In 2018, he was promoted to Senior Vice
President and CFO of BD’s Medical Segment, the company’s largest segment, where he partnered with leadership to drive growth,
profitability, and operational performance across a global medical technology portfolio. Prior to BD, he served in various finance leadership
roles at General Electric Company and Ford Motor Company. Mr. Gallagher received his MBA from the Joseph M. Katz Graduate School of Business
at the University of Pittsburgh and a B.S. in Finance from Clemson University.
“I am excited to join CONMED and look forward
to working closely with Pat and the rest of the CONMED team to further enhance the Company’s operating and financial performance,”
said John Gallagher. “CONMED has built a differentiated portfolio in high-growth surgical categories, and I look forward to partnering
with Pat and the team to drive the next chapter of value creation for our shareholders.”
About CONMED Corporation
CONMED is a medical technology
company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare
professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information,
visit www.conmed.com.
Forward-Looking Statements
This press release may contain
forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual
results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures.
For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from
those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company’s Annual Report
on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most
recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the
SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements
made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed
in the forward-looking statements will actually occur or prove to be correct.
GRAPHIC
GRAPHIC
Filename: ea029501601_ex10-1img1.jpg · Sequence: 4
Binary file (9077 bytes)
Download ea029501601_ex10-1img1.jpg
GRAPHIC
GRAPHIC
Filename: ea029501601_ex10-1img2.jpg · Sequence: 5
Binary file (5332 bytes)
Download ea029501601_ex10-1img2.jpg
GRAPHIC
GRAPHIC
Filename: ea029501601_ex99-1img1.jpg · Sequence: 6
Binary file (10768 bytes)
Download ea029501601_ex99-1img1.jpg
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 11
v3.26.1
Cover
Jun. 17, 2026
Cover [Abstract]
Document Type
8-K
Amendment Flag
false
Document Period End Date
Jun. 17, 2026
Entity File Number
001-39218
Entity Registrant Name
CONMED CORPORATION
Entity Central Index Key
0000816956
Entity Tax Identification Number
16-0977505
Entity Incorporation, State or Country Code
DE
Entity Address, Address Line One
11311 Concept Blvd
Entity Address, City or Town
Largo
Entity Address, State or Province
FL
Entity Address, Postal Zip Code
33773
City Area Code
727
Local Phone Number
392-6464
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, $0.01 par value
Trading Symbol
CNMD
Security Exchange Name
NYSE
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration